China Resources Pharmaceutical: JZYY's net profit attributable to the parent company in the first half of the year was approximately 522 million yuan, a year-on-year increase of 5.8%
According to the Zhitong Finance APP, China Resources Pharmaceutical announced the mid-term performance of JZYY for 2025, with total operating revenue of approximately 2.141 billion yuan, a year-on-year decrease of 5.79%; net profit attributable to shareholders of the listed company was approximately 522 million yuan, a year-on-year increase of 5.8%; basic earnings per share were 0.82 yuan, with a cash dividend of 5 yuan (tax included) for every 10 shares
According to the Zhitong Finance APP, China Resources Pharmaceutical (03320) announced the mid-term performance of JZYY for 2025, with total operating revenue of approximately 2.141 billion yuan, a year-on-year decrease of 5.79%; net profit attributable to shareholders of the listed company was approximately 522 million yuan, a year-on-year increase of 5.8%; basic earnings per share were 0.82 yuan, with a cash dividend of 5 yuan (including tax) for every 10 shares
